Recombinant Human Thrombopoietin Promotes Platelet Engraftment in Severe Aplastic Anemia Patients Following Treatment With Haploid Hematopoietic Stem Cell Transplantation using Modified Post-Transplantation Cyclophosphamide
•rhTPO promoted platelet recovery after Haplo-HSCT in SAA patients received PTCy.•rhTPO did not significantly impact transplant-related complications or survival.•rhTPO demonstrated good safety profiles without evident adverse reactions. Recombinant human TPO (rhTPO) promotes platelet engraftment in...
Gespeichert in:
| Veröffentlicht in: | Transplantation and cellular therapy 2024-05, Vol.30 (5), p.500-509 |
|---|---|
| Hauptverfasser: | , , , , , , , , , , , , , , , , , |
| Format: | Artikel |
| Sprache: | eng |
| Schlagworte: | |
| Online-Zugang: | Volltext |
| Tags: |
Tag hinzufügen
Keine Tags, Fügen Sie den ersten Tag hinzu!
|
| container_end_page | 509 |
|---|---|
| container_issue | 5 |
| container_start_page | 500 |
| container_title | Transplantation and cellular therapy |
| container_volume | 30 |
| creator | Fu, Andie Peng, Yizhou Cheng, Ping Wu, Jiaying Zhu, Xiaojian Yang, Yang Huang, Lifang Wang, Na Wang, Jue Xu, Jinhuan Wan, Yuling Cao, Yang Wei, Jia Xiao, Yi Meng, Fankai Cheng, Hui Zhang, Yicheng Zhang, Donghua |
| description | •rhTPO promoted platelet recovery after Haplo-HSCT in SAA patients received PTCy.•rhTPO did not significantly impact transplant-related complications or survival.•rhTPO demonstrated good safety profiles without evident adverse reactions.
Recombinant human TPO (rhTPO) promotes platelet engraftment in patients after allogeneic HSCT (allo-HSCT). However, the effects of rhTPO on platelet recovery after Haplo-HSCT in patients with severe aplastic anemia (SAA) have not been intensively studied.
We aimed to evaluate the efficacy of rhTPO on platelet engraftment in patients with SAA who were treated with Haplo-HSCT using post-transplantation cyclophosphamide (PTCy).
SAA patients who received Haplo-HSCT plus PTCy regimen were divided into the rhTPO group (with subcutaneous injection of rhTPO, n = 28) and Control group (no rhTPO administration, n = 27). The engraftment of platelet/neutrophil, platelet infusion amount, and transplant-related complications between the 2 groups were compared.
All 55 patients showed successful hematopoietic reconstitution. The median time of platelet engraftment was 11 (9 to 29) days in the rhTPO group and 14 (9 to 28) days in the Control group (P = .003). The rhTPO group had a significantly reduced amount of infused platelets compared to the Control group (2 (1 to 11.5) versus 3 (1 to 14) therapeutic doses; P = .004). There was no significant difference between the 2 groups regarding median time of neutrophil engraftment, incidence of acute graft-versus-host disease (aGVHD) and chronic GVHD (cGVHD), incidence of cytomegalovirus or Epstein–Barr virus reactivation, 3-yr overall survival rate, and failure-free-survival rate. No obvious adverse reactions were observed in the rhTPO group.
rhTPO promoted platelet engraftment, reduced the amount of transfused platelets, and demonstrated good safety profiles without evidence of adverse reactions in patients with SAA who received Haplo-HSCT using PTCy regimen. |
| doi_str_mv | 10.1016/j.jtct.2024.02.023 |
| format | Article |
| fullrecord | <record><control><sourceid>proquest_cross</sourceid><recordid>TN_cdi_proquest_miscellaneous_2942188817</recordid><sourceformat>XML</sourceformat><sourcesystem>PC</sourcesystem><els_id>S2666636724002495</els_id><sourcerecordid>2942188817</sourcerecordid><originalsourceid>FETCH-LOGICAL-c356t-9577e8f3c7ef4eae48b3c4a48c7129aff0d17ec8a9cf297140f3f3b7a6e383683</originalsourceid><addsrcrecordid>eNp9kV2LEzEUhgdR3GXdP-CF5NKbqfmYTjLgTSm7VlixuBUvQ5o52abkY0zSlf21_hVTWkW8EA7kg-c84eRtmtcEzwgm_bv9bF90mVFMuxmmtdiz5pL2fd_2rOfP_9pfNNc57zGuJMOE4ZfNBRNdx_kcXzY_v4COfmuDCgWtDl4FtNmlehOnaKHYgNb1FAtktHaqgIOCbsJDUqZ4qC0VuIdHSIAWk1O5WI0WAbxVaK2KrURGt9G5-MOGB7RJoE5t32zZoZWaXLQjWoFX5fyeRvcFPFqCcxVXIVdrKFUVAzrko-RTHK2xMKJ1zKX9l1k-aRenXczTTnk7wqvmhVEuw_V5vWq-3t5slqv27vOHj8vFXavZvC_tMOcchGGag-lAQSe2THeqE5oTOihj8Eg4aKEGbejASYcNM2zLVQ9MsF6wq-btyTul-P0AuUhvs65TqADxkCUdOkqEEIRXlJ5QnWLOCYyckvUqPUmC5TFbuZfHbOUxW4lpLVab3pz9h62H8U_L7yQr8P4EQJ3y0UKSWdf_1zDaBFU2Rvs__y_glLzu</addsrcrecordid><sourcetype>Aggregation Database</sourcetype><iscdi>true</iscdi><recordtype>article</recordtype><pqid>2942188817</pqid></control><display><type>article</type><title>Recombinant Human Thrombopoietin Promotes Platelet Engraftment in Severe Aplastic Anemia Patients Following Treatment With Haploid Hematopoietic Stem Cell Transplantation using Modified Post-Transplantation Cyclophosphamide</title><source>MEDLINE</source><source>Alma/SFX Local Collection</source><creator>Fu, Andie ; Peng, Yizhou ; Cheng, Ping ; Wu, Jiaying ; Zhu, Xiaojian ; Yang, Yang ; Huang, Lifang ; Wang, Na ; Wang, Jue ; Xu, Jinhuan ; Wan, Yuling ; Cao, Yang ; Wei, Jia ; Xiao, Yi ; Meng, Fankai ; Cheng, Hui ; Zhang, Yicheng ; Zhang, Donghua</creator><creatorcontrib>Fu, Andie ; Peng, Yizhou ; Cheng, Ping ; Wu, Jiaying ; Zhu, Xiaojian ; Yang, Yang ; Huang, Lifang ; Wang, Na ; Wang, Jue ; Xu, Jinhuan ; Wan, Yuling ; Cao, Yang ; Wei, Jia ; Xiao, Yi ; Meng, Fankai ; Cheng, Hui ; Zhang, Yicheng ; Zhang, Donghua</creatorcontrib><description>•rhTPO promoted platelet recovery after Haplo-HSCT in SAA patients received PTCy.•rhTPO did not significantly impact transplant-related complications or survival.•rhTPO demonstrated good safety profiles without evident adverse reactions.
Recombinant human TPO (rhTPO) promotes platelet engraftment in patients after allogeneic HSCT (allo-HSCT). However, the effects of rhTPO on platelet recovery after Haplo-HSCT in patients with severe aplastic anemia (SAA) have not been intensively studied.
We aimed to evaluate the efficacy of rhTPO on platelet engraftment in patients with SAA who were treated with Haplo-HSCT using post-transplantation cyclophosphamide (PTCy).
SAA patients who received Haplo-HSCT plus PTCy regimen were divided into the rhTPO group (with subcutaneous injection of rhTPO, n = 28) and Control group (no rhTPO administration, n = 27). The engraftment of platelet/neutrophil, platelet infusion amount, and transplant-related complications between the 2 groups were compared.
All 55 patients showed successful hematopoietic reconstitution. The median time of platelet engraftment was 11 (9 to 29) days in the rhTPO group and 14 (9 to 28) days in the Control group (P = .003). The rhTPO group had a significantly reduced amount of infused platelets compared to the Control group (2 (1 to 11.5) versus 3 (1 to 14) therapeutic doses; P = .004). There was no significant difference between the 2 groups regarding median time of neutrophil engraftment, incidence of acute graft-versus-host disease (aGVHD) and chronic GVHD (cGVHD), incidence of cytomegalovirus or Epstein–Barr virus reactivation, 3-yr overall survival rate, and failure-free-survival rate. No obvious adverse reactions were observed in the rhTPO group.
rhTPO promoted platelet engraftment, reduced the amount of transfused platelets, and demonstrated good safety profiles without evidence of adverse reactions in patients with SAA who received Haplo-HSCT using PTCy regimen.</description><identifier>ISSN: 2666-6367</identifier><identifier>EISSN: 2666-6367</identifier><identifier>DOI: 10.1016/j.jtct.2024.02.023</identifier><identifier>PMID: 38447750</identifier><language>eng</language><publisher>United States: Elsevier Inc</publisher><subject>Adolescent ; Adult ; Anemia, Aplastic - therapy ; Blood Platelets - drug effects ; Child ; Cyclophosphamide - therapeutic use ; Female ; Graft vs Host Disease ; Haploid hematopoietic stem cell transplantation ; Hematopoietic Stem Cell Transplantation - methods ; Humans ; Male ; Middle Aged ; Platelet engraftment ; Platelet Transfusion ; Post-transplantation cyclophosphamide ; Recombinant human thrombopoietin ; Recombinant Proteins - administration & dosage ; Recombinant Proteins - therapeutic use ; Severe aplastic anemia ; Thrombopoietin - administration & dosage ; Thrombopoietin - therapeutic use ; Transplantation, Haploidentical ; Young Adult</subject><ispartof>Transplantation and cellular therapy, 2024-05, Vol.30 (5), p.500-509</ispartof><rights>2024 The American Society for Transplantation and Cellular Therapy</rights><rights>Copyright © 2024 The American Society for Transplantation and Cellular Therapy. Published by Elsevier Inc. All rights reserved.</rights><lds50>peer_reviewed</lds50><woscitedreferencessubscribed>false</woscitedreferencessubscribed><citedby>FETCH-LOGICAL-c356t-9577e8f3c7ef4eae48b3c4a48c7129aff0d17ec8a9cf297140f3f3b7a6e383683</citedby><cites>FETCH-LOGICAL-c356t-9577e8f3c7ef4eae48b3c4a48c7129aff0d17ec8a9cf297140f3f3b7a6e383683</cites><orcidid>0000-0002-4064-8907</orcidid></display><links><openurl>$$Topenurl_article</openurl><openurlfulltext>$$Topenurlfull_article</openurlfulltext><thumbnail>$$Tsyndetics_thumb_exl</thumbnail><link.rule.ids>314,780,784,27924,27925</link.rule.ids><backlink>$$Uhttps://www.ncbi.nlm.nih.gov/pubmed/38447750$$D View this record in MEDLINE/PubMed$$Hfree_for_read</backlink></links><search><creatorcontrib>Fu, Andie</creatorcontrib><creatorcontrib>Peng, Yizhou</creatorcontrib><creatorcontrib>Cheng, Ping</creatorcontrib><creatorcontrib>Wu, Jiaying</creatorcontrib><creatorcontrib>Zhu, Xiaojian</creatorcontrib><creatorcontrib>Yang, Yang</creatorcontrib><creatorcontrib>Huang, Lifang</creatorcontrib><creatorcontrib>Wang, Na</creatorcontrib><creatorcontrib>Wang, Jue</creatorcontrib><creatorcontrib>Xu, Jinhuan</creatorcontrib><creatorcontrib>Wan, Yuling</creatorcontrib><creatorcontrib>Cao, Yang</creatorcontrib><creatorcontrib>Wei, Jia</creatorcontrib><creatorcontrib>Xiao, Yi</creatorcontrib><creatorcontrib>Meng, Fankai</creatorcontrib><creatorcontrib>Cheng, Hui</creatorcontrib><creatorcontrib>Zhang, Yicheng</creatorcontrib><creatorcontrib>Zhang, Donghua</creatorcontrib><title>Recombinant Human Thrombopoietin Promotes Platelet Engraftment in Severe Aplastic Anemia Patients Following Treatment With Haploid Hematopoietic Stem Cell Transplantation using Modified Post-Transplantation Cyclophosphamide</title><title>Transplantation and cellular therapy</title><addtitle>Transplant Cell Ther</addtitle><description>•rhTPO promoted platelet recovery after Haplo-HSCT in SAA patients received PTCy.•rhTPO did not significantly impact transplant-related complications or survival.•rhTPO demonstrated good safety profiles without evident adverse reactions.
Recombinant human TPO (rhTPO) promotes platelet engraftment in patients after allogeneic HSCT (allo-HSCT). However, the effects of rhTPO on platelet recovery after Haplo-HSCT in patients with severe aplastic anemia (SAA) have not been intensively studied.
We aimed to evaluate the efficacy of rhTPO on platelet engraftment in patients with SAA who were treated with Haplo-HSCT using post-transplantation cyclophosphamide (PTCy).
SAA patients who received Haplo-HSCT plus PTCy regimen were divided into the rhTPO group (with subcutaneous injection of rhTPO, n = 28) and Control group (no rhTPO administration, n = 27). The engraftment of platelet/neutrophil, platelet infusion amount, and transplant-related complications between the 2 groups were compared.
All 55 patients showed successful hematopoietic reconstitution. The median time of platelet engraftment was 11 (9 to 29) days in the rhTPO group and 14 (9 to 28) days in the Control group (P = .003). The rhTPO group had a significantly reduced amount of infused platelets compared to the Control group (2 (1 to 11.5) versus 3 (1 to 14) therapeutic doses; P = .004). There was no significant difference between the 2 groups regarding median time of neutrophil engraftment, incidence of acute graft-versus-host disease (aGVHD) and chronic GVHD (cGVHD), incidence of cytomegalovirus or Epstein–Barr virus reactivation, 3-yr overall survival rate, and failure-free-survival rate. No obvious adverse reactions were observed in the rhTPO group.
rhTPO promoted platelet engraftment, reduced the amount of transfused platelets, and demonstrated good safety profiles without evidence of adverse reactions in patients with SAA who received Haplo-HSCT using PTCy regimen.</description><subject>Adolescent</subject><subject>Adult</subject><subject>Anemia, Aplastic - therapy</subject><subject>Blood Platelets - drug effects</subject><subject>Child</subject><subject>Cyclophosphamide - therapeutic use</subject><subject>Female</subject><subject>Graft vs Host Disease</subject><subject>Haploid hematopoietic stem cell transplantation</subject><subject>Hematopoietic Stem Cell Transplantation - methods</subject><subject>Humans</subject><subject>Male</subject><subject>Middle Aged</subject><subject>Platelet engraftment</subject><subject>Platelet Transfusion</subject><subject>Post-transplantation cyclophosphamide</subject><subject>Recombinant human thrombopoietin</subject><subject>Recombinant Proteins - administration & dosage</subject><subject>Recombinant Proteins - therapeutic use</subject><subject>Severe aplastic anemia</subject><subject>Thrombopoietin - administration & dosage</subject><subject>Thrombopoietin - therapeutic use</subject><subject>Transplantation, Haploidentical</subject><subject>Young Adult</subject><issn>2666-6367</issn><issn>2666-6367</issn><fulltext>true</fulltext><rsrctype>article</rsrctype><creationdate>2024</creationdate><recordtype>article</recordtype><sourceid>EIF</sourceid><recordid>eNp9kV2LEzEUhgdR3GXdP-CF5NKbqfmYTjLgTSm7VlixuBUvQ5o52abkY0zSlf21_hVTWkW8EA7kg-c84eRtmtcEzwgm_bv9bF90mVFMuxmmtdiz5pL2fd_2rOfP_9pfNNc57zGuJMOE4ZfNBRNdx_kcXzY_v4COfmuDCgWtDl4FtNmlehOnaKHYgNb1FAtktHaqgIOCbsJDUqZ4qC0VuIdHSIAWk1O5WI0WAbxVaK2KrURGt9G5-MOGB7RJoE5t32zZoZWaXLQjWoFX5fyeRvcFPFqCcxVXIVdrKFUVAzrko-RTHK2xMKJ1zKX9l1k-aRenXczTTnk7wqvmhVEuw_V5vWq-3t5slqv27vOHj8vFXavZvC_tMOcchGGag-lAQSe2THeqE5oTOihj8Eg4aKEGbejASYcNM2zLVQ9MsF6wq-btyTul-P0AuUhvs65TqADxkCUdOkqEEIRXlJ5QnWLOCYyckvUqPUmC5TFbuZfHbOUxW4lpLVab3pz9h62H8U_L7yQr8P4EQJ3y0UKSWdf_1zDaBFU2Rvs__y_glLzu</recordid><startdate>202405</startdate><enddate>202405</enddate><creator>Fu, Andie</creator><creator>Peng, Yizhou</creator><creator>Cheng, Ping</creator><creator>Wu, Jiaying</creator><creator>Zhu, Xiaojian</creator><creator>Yang, Yang</creator><creator>Huang, Lifang</creator><creator>Wang, Na</creator><creator>Wang, Jue</creator><creator>Xu, Jinhuan</creator><creator>Wan, Yuling</creator><creator>Cao, Yang</creator><creator>Wei, Jia</creator><creator>Xiao, Yi</creator><creator>Meng, Fankai</creator><creator>Cheng, Hui</creator><creator>Zhang, Yicheng</creator><creator>Zhang, Donghua</creator><general>Elsevier Inc</general><scope>CGR</scope><scope>CUY</scope><scope>CVF</scope><scope>ECM</scope><scope>EIF</scope><scope>NPM</scope><scope>AAYXX</scope><scope>CITATION</scope><scope>7X8</scope><orcidid>https://orcid.org/0000-0002-4064-8907</orcidid></search><sort><creationdate>202405</creationdate><title>Recombinant Human Thrombopoietin Promotes Platelet Engraftment in Severe Aplastic Anemia Patients Following Treatment With Haploid Hematopoietic Stem Cell Transplantation using Modified Post-Transplantation Cyclophosphamide</title><author>Fu, Andie ; Peng, Yizhou ; Cheng, Ping ; Wu, Jiaying ; Zhu, Xiaojian ; Yang, Yang ; Huang, Lifang ; Wang, Na ; Wang, Jue ; Xu, Jinhuan ; Wan, Yuling ; Cao, Yang ; Wei, Jia ; Xiao, Yi ; Meng, Fankai ; Cheng, Hui ; Zhang, Yicheng ; Zhang, Donghua</author></sort><facets><frbrtype>5</frbrtype><frbrgroupid>cdi_FETCH-LOGICAL-c356t-9577e8f3c7ef4eae48b3c4a48c7129aff0d17ec8a9cf297140f3f3b7a6e383683</frbrgroupid><rsrctype>articles</rsrctype><prefilter>articles</prefilter><language>eng</language><creationdate>2024</creationdate><topic>Adolescent</topic><topic>Adult</topic><topic>Anemia, Aplastic - therapy</topic><topic>Blood Platelets - drug effects</topic><topic>Child</topic><topic>Cyclophosphamide - therapeutic use</topic><topic>Female</topic><topic>Graft vs Host Disease</topic><topic>Haploid hematopoietic stem cell transplantation</topic><topic>Hematopoietic Stem Cell Transplantation - methods</topic><topic>Humans</topic><topic>Male</topic><topic>Middle Aged</topic><topic>Platelet engraftment</topic><topic>Platelet Transfusion</topic><topic>Post-transplantation cyclophosphamide</topic><topic>Recombinant human thrombopoietin</topic><topic>Recombinant Proteins - administration & dosage</topic><topic>Recombinant Proteins - therapeutic use</topic><topic>Severe aplastic anemia</topic><topic>Thrombopoietin - administration & dosage</topic><topic>Thrombopoietin - therapeutic use</topic><topic>Transplantation, Haploidentical</topic><topic>Young Adult</topic><toplevel>peer_reviewed</toplevel><toplevel>online_resources</toplevel><creatorcontrib>Fu, Andie</creatorcontrib><creatorcontrib>Peng, Yizhou</creatorcontrib><creatorcontrib>Cheng, Ping</creatorcontrib><creatorcontrib>Wu, Jiaying</creatorcontrib><creatorcontrib>Zhu, Xiaojian</creatorcontrib><creatorcontrib>Yang, Yang</creatorcontrib><creatorcontrib>Huang, Lifang</creatorcontrib><creatorcontrib>Wang, Na</creatorcontrib><creatorcontrib>Wang, Jue</creatorcontrib><creatorcontrib>Xu, Jinhuan</creatorcontrib><creatorcontrib>Wan, Yuling</creatorcontrib><creatorcontrib>Cao, Yang</creatorcontrib><creatorcontrib>Wei, Jia</creatorcontrib><creatorcontrib>Xiao, Yi</creatorcontrib><creatorcontrib>Meng, Fankai</creatorcontrib><creatorcontrib>Cheng, Hui</creatorcontrib><creatorcontrib>Zhang, Yicheng</creatorcontrib><creatorcontrib>Zhang, Donghua</creatorcontrib><collection>Medline</collection><collection>MEDLINE</collection><collection>MEDLINE (Ovid)</collection><collection>MEDLINE</collection><collection>MEDLINE</collection><collection>PubMed</collection><collection>CrossRef</collection><collection>MEDLINE - Academic</collection><jtitle>Transplantation and cellular therapy</jtitle></facets><delivery><delcategory>Remote Search Resource</delcategory><fulltext>fulltext</fulltext></delivery><addata><au>Fu, Andie</au><au>Peng, Yizhou</au><au>Cheng, Ping</au><au>Wu, Jiaying</au><au>Zhu, Xiaojian</au><au>Yang, Yang</au><au>Huang, Lifang</au><au>Wang, Na</au><au>Wang, Jue</au><au>Xu, Jinhuan</au><au>Wan, Yuling</au><au>Cao, Yang</au><au>Wei, Jia</au><au>Xiao, Yi</au><au>Meng, Fankai</au><au>Cheng, Hui</au><au>Zhang, Yicheng</au><au>Zhang, Donghua</au><format>journal</format><genre>article</genre><ristype>JOUR</ristype><atitle>Recombinant Human Thrombopoietin Promotes Platelet Engraftment in Severe Aplastic Anemia Patients Following Treatment With Haploid Hematopoietic Stem Cell Transplantation using Modified Post-Transplantation Cyclophosphamide</atitle><jtitle>Transplantation and cellular therapy</jtitle><addtitle>Transplant Cell Ther</addtitle><date>2024-05</date><risdate>2024</risdate><volume>30</volume><issue>5</issue><spage>500</spage><epage>509</epage><pages>500-509</pages><issn>2666-6367</issn><eissn>2666-6367</eissn><abstract>•rhTPO promoted platelet recovery after Haplo-HSCT in SAA patients received PTCy.•rhTPO did not significantly impact transplant-related complications or survival.•rhTPO demonstrated good safety profiles without evident adverse reactions.
Recombinant human TPO (rhTPO) promotes platelet engraftment in patients after allogeneic HSCT (allo-HSCT). However, the effects of rhTPO on platelet recovery after Haplo-HSCT in patients with severe aplastic anemia (SAA) have not been intensively studied.
We aimed to evaluate the efficacy of rhTPO on platelet engraftment in patients with SAA who were treated with Haplo-HSCT using post-transplantation cyclophosphamide (PTCy).
SAA patients who received Haplo-HSCT plus PTCy regimen were divided into the rhTPO group (with subcutaneous injection of rhTPO, n = 28) and Control group (no rhTPO administration, n = 27). The engraftment of platelet/neutrophil, platelet infusion amount, and transplant-related complications between the 2 groups were compared.
All 55 patients showed successful hematopoietic reconstitution. The median time of platelet engraftment was 11 (9 to 29) days in the rhTPO group and 14 (9 to 28) days in the Control group (P = .003). The rhTPO group had a significantly reduced amount of infused platelets compared to the Control group (2 (1 to 11.5) versus 3 (1 to 14) therapeutic doses; P = .004). There was no significant difference between the 2 groups regarding median time of neutrophil engraftment, incidence of acute graft-versus-host disease (aGVHD) and chronic GVHD (cGVHD), incidence of cytomegalovirus or Epstein–Barr virus reactivation, 3-yr overall survival rate, and failure-free-survival rate. No obvious adverse reactions were observed in the rhTPO group.
rhTPO promoted platelet engraftment, reduced the amount of transfused platelets, and demonstrated good safety profiles without evidence of adverse reactions in patients with SAA who received Haplo-HSCT using PTCy regimen.</abstract><cop>United States</cop><pub>Elsevier Inc</pub><pmid>38447750</pmid><doi>10.1016/j.jtct.2024.02.023</doi><tpages>10</tpages><orcidid>https://orcid.org/0000-0002-4064-8907</orcidid></addata></record> |
| fulltext | fulltext |
| identifier | ISSN: 2666-6367 |
| ispartof | Transplantation and cellular therapy, 2024-05, Vol.30 (5), p.500-509 |
| issn | 2666-6367 2666-6367 |
| language | eng |
| recordid | cdi_proquest_miscellaneous_2942188817 |
| source | MEDLINE; Alma/SFX Local Collection |
| subjects | Adolescent Adult Anemia, Aplastic - therapy Blood Platelets - drug effects Child Cyclophosphamide - therapeutic use Female Graft vs Host Disease Haploid hematopoietic stem cell transplantation Hematopoietic Stem Cell Transplantation - methods Humans Male Middle Aged Platelet engraftment Platelet Transfusion Post-transplantation cyclophosphamide Recombinant human thrombopoietin Recombinant Proteins - administration & dosage Recombinant Proteins - therapeutic use Severe aplastic anemia Thrombopoietin - administration & dosage Thrombopoietin - therapeutic use Transplantation, Haploidentical Young Adult |
| title | Recombinant Human Thrombopoietin Promotes Platelet Engraftment in Severe Aplastic Anemia Patients Following Treatment With Haploid Hematopoietic Stem Cell Transplantation using Modified Post-Transplantation Cyclophosphamide |
| url | https://sfx.bib-bvb.de/sfx_tum?ctx_ver=Z39.88-2004&ctx_enc=info:ofi/enc:UTF-8&ctx_tim=2024-12-28T03%3A34%3A25IST&url_ver=Z39.88-2004&url_ctx_fmt=infofi/fmt:kev:mtx:ctx&rfr_id=info:sid/primo.exlibrisgroup.com:primo3-Article-proquest_cross&rft_val_fmt=info:ofi/fmt:kev:mtx:journal&rft.genre=article&rft.atitle=Recombinant%20Human%20Thrombopoietin%20Promotes%20Platelet%20Engraftment%20in%20Severe%20Aplastic%20Anemia%20Patients%20Following%20Treatment%20With%20Haploid%20Hematopoietic%20Stem%20Cell%20Transplantation%20using%20Modified%20Post-Transplantation%20Cyclophosphamide&rft.jtitle=Transplantation%20and%20cellular%20therapy&rft.au=Fu,%20Andie&rft.date=2024-05&rft.volume=30&rft.issue=5&rft.spage=500&rft.epage=509&rft.pages=500-509&rft.issn=2666-6367&rft.eissn=2666-6367&rft_id=info:doi/10.1016/j.jtct.2024.02.023&rft_dat=%3Cproquest_cross%3E2942188817%3C/proquest_cross%3E%3Curl%3E%3C/url%3E&disable_directlink=true&sfx.directlink=off&sfx.report_link=0&rft_id=info:oai/&rft_pqid=2942188817&rft_id=info:pmid/38447750&rft_els_id=S2666636724002495&rfr_iscdi=true |